The therapeutic prospect of zinc oxide nanoparticles in experimentally induced diabetic nephropathy

Tissue Barriers. 2023 Jan 2;11(1):2069966. doi: 10.1080/21688370.2022.2069966. Epub 2022 May 3.

Abstract

Diabetic nephropathy (DN) is the most frequent cause of end-stage renal failure. Zinc oxide nanoparticles (ZnO-NPs) are promising antidiabetic agents. Our aim was to evaluate the prospective efficacy of ZnO-NPs in treating DN in streptozotocin-induced diabetic rats. Rats were randomly dispersed into three sets: control group, DN group and DN + ZnO-NPs group. ZnO-NPs were given at a dose of 10 mg/kg/day by oral gavage for 4 weeks. Urine and blood samples were processed for biochemical analyses. Kidney samples were managed for light and electron microscopy studies. Immune histochemical staining of P53, aquaporin11 (AQP11) and mechanistic target of rapamycin (mTOR) were performed. Gene analyses of nephrin, podocin, beclin-1, LC3 and p62 were done. Administration of ZnO-NPs ameliorated the functional and histopathological alterations of the kidney in a rat model of diabetic nephropathy. ZnO-NPs retained the constancy of the glomerular filtration barrier and restored almost normal renal structure. This was confirmed by upregulation of mRNA expression of podocyte markers (nephrin and podocin) and AQP11 immune histochemical expression in the renal tubules. The beneficial outcomes of ZnO-NPs might be attributed to activation of autophagy through inhibiting mTOR signaling pathway. ZnO-NPs enhanced beclin-1 and LC3 mRNA expressions and reduced p62 mRNA expression. ZnO-NPs also exerted anti-apoptotic potential (evidenced by the decrease in p53 immune expression), anti-inflammatory and anti-oxidant effect [endorsed by suppression of serum cyclooxygenase-2 (COX-2) enzyme activity, tissue nuclear factor kappa beta (NF-κB) level and blood hypoxia-inducible factors (HIF-1α) level]. These results may point the way to an effective therapy of DN.Abbreviations: AQP11 Aquaporin11; BUN: Blood urea nitrogen; COX-2: Cyclooxygenase-2; DAB: 3, 3'-diaminobenzidine; DM: Diabetes mellitus; DN: Diabetic nephropathy; ELISA: Enzyme-linked immunosorbent assay; H&E: Hematoxylin & eosin; HIF-1α: Hypoxia-inducible factors; iNOS: inducible nitric oxide synthase; LC3: Microtubule-associated protein 1 light chain 3; mTOR: Mechanistic target of rapamycin; NF-κB: Nuclear factor kappa beta; NPs: Nanoparticles; PAS: Periodic acid Schiff; PCR: Polymerase chain reaction; PGE2: Prostaglandin E2; ROS: Reactive oxygen species; STZ: Streptozotocin; X ± SEM: Mean ± standard error of means; Zn: Zinc; ZnO-NPs: Zinc oxide nanoparticles.

Keywords: Autophagy; diabetic nephropathy; mTOR; rats; zinc oxide nanoparticles.

MeSH terms

  • Animals
  • Beclin-1 / metabolism
  • Cyclooxygenase 2 / metabolism
  • Cyclooxygenase 2 / therapeutic use
  • Diabetes Mellitus, Experimental* / drug therapy
  • Diabetes Mellitus, Experimental* / metabolism
  • Diabetic Nephropathies* / drug therapy
  • Hypoxia
  • NF-kappa B / metabolism
  • Nanoparticles*
  • Prospective Studies
  • RNA, Messenger / therapeutic use
  • Rats
  • Sirolimus / therapeutic use
  • Streptozocin / pharmacology
  • Streptozocin / therapeutic use
  • TOR Serine-Threonine Kinases / metabolism
  • TOR Serine-Threonine Kinases / therapeutic use
  • Tumor Suppressor Protein p53
  • Zinc Oxide* / metabolism
  • Zinc Oxide* / pharmacology
  • Zinc Oxide* / therapeutic use

Substances

  • Zinc Oxide
  • Cyclooxygenase 2
  • NF-kappa B
  • Streptozocin
  • Beclin-1
  • Tumor Suppressor Protein p53
  • TOR Serine-Threonine Kinases
  • Sirolimus
  • RNA, Messenger

Grants and funding

This study was not funded by any source.